TG4050 is a virus-based therapeutic vaccine that incorporates a sequence of neoantigens (patient-specific mutations) selected by NEC‘s neoantigen prediction system into Transgene’s myvac®. It is designed to stimulate the immune system of patient in order to prime an innate and an adaptive response able to destroy tumor cells.

Details of clinical trial
Ovarian cancer (linked to clinicaltrials.gov)
Head and neck cancer(linked to clinicaltrials.gov)

NECVAX-NEO1 is an oral, Salmonella-based therapeutic vaccine that incorporates a sequence of neoantigens (patient-specific mutations) selected by the NEC Immune Profiler. It is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. The NECVAX-NEO1 program initially co-developed with VAXIMM was acquired by NEC OncoImmunity following an asset acquisition deal.

Details of clinical trial
Various cancer (linked to clinicaltrials.gov)